<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01412593</url>
  </required_header>
  <id_info>
    <org_study_id>LDRC001SC</org_study_id>
    <nct_id>NCT01412593</nct_id>
  </id_info>
  <brief_title>Intra-hepatic Artery Bone Marrow Derived Stem Cells Infusion for the Treatment of Advanced Liver Cirrhosis</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>King Saud University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>King Saud University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Liver disease is a common medical problem in Saudi Arabia. Early studies indicated that&#xD;
      around 10% of the Saudi population is either infected with hepatitis B or C. An estimated 12%&#xD;
      of chronic HCV and HBV patients undergoing liver biopsy from Saudi centers have cirrhosis. Of&#xD;
      these 3-5% would decompensate yearly thereby requiring liver transplantation. Based on the&#xD;
      most recent national census figures, and a 1-2% prevalence rate of HBV and HCV nationwide, an&#xD;
      estimated 1,000 patients would require liver transplantation on a yearly basis for&#xD;
      decompensated cirrhosis.&#xD;
&#xD;
      Liver transplantation is the only available life saving treatment for patients with end stage&#xD;
      liver disease. Unfortunately less than 100 liver transplantations are performed in Saudi&#xD;
      Arabia in three centers. Around 100 other patients travel abroad for transplantation annually&#xD;
      while all other patients progressively deteriorate and eventually die from the complications&#xD;
      of decompensated liver cirrhosis.&#xD;
&#xD;
      In addition, even in patients who are listed for liver transplantation, often patients are&#xD;
      too sick to wait on the transplant list that often takes more than a year and the on-list&#xD;
      mortality is high. A procedure or an intervention that may help to stabilize liver function&#xD;
      in order to help patients survive on the transplant list while awaiting liver transplantation&#xD;
      would be of immense benefit. Examples of such interventions are already approved and used in&#xD;
      some centers like the MARS system.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>September 2011</start_date>
  <completion_date type="Anticipated">September 2013</completion_date>
  <primary_completion_date type="Anticipated">September 2012</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improvement of liver function measured by improvement in the model for end-stage liver disease (MELD) score.</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>End Stage Liver Disease</condition>
  <arm_group>
    <arm_group_label>Stem cell transplant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Stem cell transplant</intervention_name>
    <description>Patients randomized to the intervention arm will be admitted to the Liver Care Unit. Granulocyte colony-stimulating factor (G-CSF; 300mcg/mL) will be administered for 1 day as a single daily subcutaneous dose. This dose is sufficient to induce 10 folds enrichment for bone marrow cells.</description>
    <arm_group_label>Stem cell transplant</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt;18 years&#xD;
&#xD;
          -  Clinically diagnosed liver cirrhosis by any of the following: ultrasound/MRI/ CT/ +&#xD;
             tissue biopsy.&#xD;
&#xD;
          -  MELD score ≥ 18 and &lt;35&#xD;
&#xD;
          -  Ability to sign an informed consent&#xD;
&#xD;
          -  Refused by liver transplant program or labeled as not a liver transplant candidate,&#xD;
             decided by at least 3 transplant physicians&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  On a liver transplantation waiting list&#xD;
&#xD;
          -  Questionable diagnosis of cirrhosis&#xD;
&#xD;
          -  Prior history of organ transplantation&#xD;
&#xD;
          -  Past history of malignancy within the 2 years prior to inclusion&#xD;
&#xD;
          -  Probable or diagnosis of hepatocellular carcinoma&#xD;
&#xD;
          -  Major hepatic vascular thrombosis (hepatic artery, or portal or hepatic veins)&#xD;
&#xD;
          -  Serious cardiovascular or respiratory disease, or other medical condition with a high&#xD;
             anticipated mortality within twelve months&#xD;
&#xD;
          -  Current or recent (within the past 4 weeks) use of vasoactive drugs (Epinephrine,&#xD;
             Norepinephrine, Vasopressin, Dopamine, terlipressin)&#xD;
&#xD;
          -  Type-1 (acute) hepatorenal syndrome&#xD;
&#xD;
          -  Levels of serum creatinine &gt;150 µmol/ml and/or creatinine clearance &lt;30 ml/min (as&#xD;
             calculated by MDRD system)&#xD;
&#xD;
          -  Documented or suspected ongoing infection&#xD;
&#xD;
          -  Active or recent gastrointestinal bleeding episode (in the previous 4 weeks)&#xD;
&#xD;
          -  Active alcohol abuse extending to within the previous six months&#xD;
&#xD;
          -  Pulmonary hypertension (PAP &gt; 35 mmHg), porto-pulmonary hypertension or&#xD;
             hepatopulmonary syndrome&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  HIV infection&#xD;
&#xD;
          -  Active or past drug addiction within the preceding 6 months&#xD;
&#xD;
          -  History of serious or uncontrolled psychiatric disease or depression&#xD;
&#xD;
          -  Contraindications to the angiography procedures (e.g. arterial aneurysm, kinking,&#xD;
             thrombosis)&#xD;
&#xD;
          -  Contraindications for bone marrow biopsy (e.g. bleeding diathesis)&#xD;
&#xD;
          -  Prior shunt operative shunt procedure&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ayman Abdo, Associate Professor</last_name>
    <phone>+96614670810</phone>
    <email>aabdo@ksu.edu.sa</email>
  </overall_contact>
  <location>
    <facility>
      <name>King Khalid University Hospital</name>
      <address>
        <city>Riyadh</city>
        <zip>11461</zip>
        <country>Saudi Arabia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Saudi Arabia</country>
  </location_countries>
  <verification_date>May 2011</verification_date>
  <study_first_submitted>August 8, 2011</study_first_submitted>
  <study_first_submitted_qc>August 8, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 9, 2011</study_first_posted>
  <last_update_submitted>August 8, 2011</last_update_submitted>
  <last_update_submitted_qc>August 8, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 9, 2011</last_update_posted>
  <responsible_party>
    <name_title>Dr Ayman Abdo</name_title>
    <organization>King Saud University</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>End Stage Liver Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

